The candidate has already entered a complex test, and one of the few applicants is being evaluated with several thousand people to see if they are effective enough to discharge regulatory approval.
Sinopharm is verifying the potential vaccine in the United Arab Emirates in a phase 3 trial that is expected to recruit another 15,000 people because China has very few new instances to be a useful verification site.
The state-owned company will also be running for Pakistan as part of a test deal, the Wall Street Journal reported.
The shooting did not cause serious side effects, according to an article published Thursday in the Journal of the American Medical Association (JAMA) through scientists who are part of Sinopharm and other Chinese-based government and disease study institutes.
The effects occurred on the knowledge of 320 healthy adults in phase 1 and 2 trials.
The candidate triggered physically powerful antibody responses in inoculated individuals, however, it is unknown whether this is sufficient to prevent COVID-19 infection, the researchers advancing the vaccine said in the paper.
Sinopharm’s president told state media last month that a potential vaccine could be available until the end of this year and that Phase 3 testing will be completed in about 3 months.
The new coronavirus, which has killed more than 750,000 people worldwide, has sparked a race to expand a vaccine. More than 150 candidate vaccines are being developed and tested worldwide.
Russia has become the first country to grant regulatory approval to a vaccine after less than two months of human testing, and a vaccine developed through the Chinese company CanSino Bilogics allowed its use in the military.
China leads the progression of at least 8 candidate vaccines at other stages of clinical trials.
This story was published from a firm thread without converting the text. Only the name has been changed.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.